Pan‐cancer population pharmacokinetics and exposure‐safety and ‐efficacy analyses of atezolizumab in patients with high tumor mutational burden

We retrospectively investigated the pharmacokinetics and exposure‐efficacy/safety relationships of single‐agent atezolizumab based on tissue tumor mutational burden (tTMB) status (high vs low [≥16 vs <16 mutations/megabase]) in a pan‐tumor population from seven clinical trials. Data sources inclu...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Pharmacol Res Perspect
Egile Nagusiak: Shemesh, Colby S., Chan, Phyllis, Legrand, Fatema A., Shames, David S., Das Thakur, Meghna, Shi, Jane, Bailey, Lorna, Vadhavkar, Shweta, He, Xian, Zhang, Wei, Bruno, René
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2020
Gaiak:
Original Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7689240/
https://ncbi.nlm.nih.gov/pubmed/33241650
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.685
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak